DeepMind’s AlphaGenome AI system can analyze up to one million DNA base pairs to predict functional effects of noncoding genetic variations linked to diseases like cancer and rare disorders. This technological advance promises to transform personalized medicine by elucidating regulatory DNA elements previously difficult to characterize. Researchers anticipate broad applications in genomic research and diagnostics, accelerating discovery of disease mechanisms tied to noncoding regions of the human genome.